# Nalbuphine Versus Morphine for Perioperative Tumor Ablation

> **NCT05073744** · PHASE4 · UNKNOWN · sponsor: **Zhongda Hospital** · enrollment: 316 (estimated)

## Conditions studied

- Nalbuphine Allergy
- Ablation
- Safety

## Interventions

- **DRUG:** Nalbuphine
- **DRUG:** Morphine

## Key facts

- **NCT ID:** NCT05073744
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-05
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2022-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05073744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05073744, "Nalbuphine Versus Morphine for Perioperative Tumor Ablation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05073744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*